Trial of RAD001 in Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1b pre-operative lung cancer trial wherein patients with operable lung cancer
will be treated with RAD001 to evaluate the target effects of this compounds on relevant
molecular pathways and on the 18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose (FDG) uptake
of the tumor by a positron emission tomography (PET) scan at baseline and immediately prior
to surgery. The safety profile of RAD001 will also be evaluated.